Immpact Bio USA Inc. has obtained IND clearance from the FDA for IMPT-514, a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with multiple sclerosis (MS). A phase I trial will focus on patients who have suboptimal disease control despite prior treatment with high efficacy disease-modifying therapies in all forms of MS.
Immpact Bio USA Inc. has received FDA clearance of its IND application for IMPT-514, a bispecific CD19/CD20 chimeric antigen receptor (CAR) T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
Immpact Bio USA Inc. has announced clearance of its IND application by the FDA for IMPT-314, a bispecific OR-Gate autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell antigens CD19 and CD20.
Cancer therapy developer Immpact Bio USA Inc. has raised $111 million to further its "logic gate"-based CAR T-cell platform, the source of a CD19/CD20 bispecific in phase I testing for B-cell non-Hodgkin lymphoma patients whose disease has returned or who has stopped responding to treatment. New data from that study, showing complete remissions in seven of eight patients treated, accompanied the appointment of a new president and CEO for the company as well as a new board chair.
